Related Experiment Video
Updated: Jun 29, 2025
04:33
Methods for Detecting Cough and Airway Inflammation in Mice
Published on: August 2, 2024
616
Inhibitory Effect of P22077 on Airway Inflammation in Rats with COPD and Its Mechanism
Di Zeng1, Wenbo Zhang2, Xiaoju Chen3
1Department of General Practice, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China.
Summary
P22077 effectively reduces airway inflammation and emphysema in a rat model of Chronic Obstructive Pulmonary Disease (COPD). This therapeutic effect is linked to the inhibition of the NLRP3 inflammasome pathway, offering a potential treatment strategy.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Inflammation Research
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is a major global health issue characterized by persistent airway inflammation.
- Current treatments for COPD offer limited efficacy in managing disease progression and symptoms.
Purpose of the Study:
- To investigate the pharmacological effects of P22077 on lipopolysaccharide and cigarette smoke-induced airway inflammation in a COPD rat model.
- To elucidate the therapeutic mechanism of P22077 in mitigating COPD-related pathology.
Main Methods:
- A COPD rat model was established using lipopolysaccharide and cigarette smoke exposure.
- Animals were treated with either vehicle or P22077, followed by analysis of serum, bronchoalveolar lavage fluid (BALF), and lung tissues.
- Histopathological analyses included Hematoxylin and Eosin (H&E) and Periodic Acid-Schiff (PAS) staining.
Main Results:
- P22077 treatment significantly reduced airway inflammation, leukocyte recruitment, and the levels of interleukin-18 (IL-18) and interleukin-1β (IL-1β) in BALF and serum.
- Histological examination revealed that P22077 attenuated emphysema, immune cell infiltration, airway wall destruction, and goblet cell hyperplasia.
- P22077 suppressed the activation of the NLRP3/ASC/Caspase 1 inflammasome complex, thereby inhibiting IL-1β and IL-18 production.
Conclusions:
- P22077 demonstrates significant therapeutic potential for COPD by reducing airway inflammation and inflammatory cell aggregation.
- The mechanism of action involves the down-regulation of the NLRP3 inflammasome signaling pathway.
- P22077 represents a promising candidate for the development of novel COPD therapeutics.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:26COPD: Management Using Bronchodilators and Corticosteroids
202
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
202
01:20COPD: Pathogenesis and Clinical Features
269
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
269
01:17Drugs Used in Lower Respiratory Disorders: Overview
437
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
437
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K